Curcuma longa commonly known as turmeric has been used in Indian Ayurvedic medicine as a constituent to
treat various disorders. It is by now clear that principal curcuminoid of turmeric; curcumin, a yellow pigment, is responsible
for these beneficiary activities. The aim of the present study was to evaluate anti-mycobacterial effect of curcumin
(CMN) on intracellular growth of MDR clinical isolates of Mycobacterium tuberculosis (MTB). Curcumin was evaluated
for its efficacy to inhibit the intracellular growth of MTB H37Rv and two MDR clinical isolates in Raw 264.7 cell line using
CFU assay. Resazurin microtiter plate assay (REMA) was used to evaluate its direct anti-mycobacterial activity.
Curcumin, though did not show direct anti-mycobacterial activity against three MTB strains, exhibited dose dependent inhibition of intracellular growth for MTB H37Rv as well as two MDR clinical isolates. These results suggest that CMN
could be a potential candidate for future, novel adjunctive anti-TB therapy.